145 related articles for article (PubMed ID: 27163501)
1. Pharmacokinetics of the Long-Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function.
Linnebjerg H; Choi SL; Lam EC; Mace KF; Hodgson TS; Sinha VP
Clin Pharmacol Drug Dev; 2016 May; 5(3):216-24. PubMed ID: 27163501
[TBL] [Abstract][Full Text] [Related]
2. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects.
Sinha VP; Choi SL; Soon DK; Mace KF; Yeo KP; Lim ST; Howey DC
J Clin Pharmacol; 2014 Jul; 54(7):792-9. PubMed ID: 24504686
[TBL] [Abstract][Full Text] [Related]
3. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus.
Sinha VP; Howey DC; Choi SL; Mace KF; Heise T
Diabetes Obes Metab; 2014 Apr; 16(4):344-50. PubMed ID: 24118909
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment.
Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald DL
Epilepsy Res; 2014 Jul; 108(5):891-901. PubMed ID: 24725807
[TBL] [Abstract][Full Text] [Related]
5. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
Boulton DW; Li L; Frevert EU; Tang A; Castaneda L; Vachharajani NN; Kornhauser DM; Patel CG
Clin Pharmacokinet; 2011 Apr; 50(4):253-65. PubMed ID: 21348538
[TBL] [Abstract][Full Text] [Related]
6. A clinical utility index for selecting an optimal insulin dosing algorithm for LY2605541 in patients with type 2 diabetes pretreated with basal insulin.
Manner DH; Luo J; Qu Y; Berry S; Gaydos BL; Jacober SJ
Diabetes Technol Ther; 2014 Aug; 16(8):499-505. PubMed ID: 24825416
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency.
Chapelsky MC; Thompson-Culkin K; Miller AK; Sack M; Blum R; Freed MI
J Clin Pharmacol; 2003 Mar; 43(3):252-9. PubMed ID: 12638393
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment.
Granhall C; Søndergaard FL; Thomsen M; Anderson TW
Clin Pharmacokinet; 2018 Dec; 57(12):1571-1580. PubMed ID: 29623579
[TBL] [Abstract][Full Text] [Related]
11. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction.
Gupta SK; Pittenger AL; Swan SK; Marbury TC; Tobillo E; Batra V; Sack M; Glue P; Jacobs S; Affrime M
J Clin Pharmacol; 2002 Oct; 42(10):1109-15. PubMed ID: 12362925
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
[TBL] [Abstract][Full Text] [Related]
13. A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis.
Riccobene T; Jakate A; Rank D
J Clin Pharmacol; 2014 Jul; 54(7):742-52. PubMed ID: 24431097
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
Zhou XJ; Swan S; Smith WB; Marbury TC; Dubuc-Patrick G; Chao GC; Brown NA
Antimicrob Agents Chemother; 2007 Dec; 51(12):4231-5. PubMed ID: 17875994
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.
Brody SR; Humphreys MH; Gambertoglio JG; Schoenfeld P; Cundy KC; Aweeka FT
Clin Pharmacol Ther; 1999 Jan; 65(1):21-8. PubMed ID: 9951427
[TBL] [Abstract][Full Text] [Related]
17. Insulin degludec: pharmacokinetics in patients with renal impairment.
Kiss I; Arold G; Roepstorff C; Bøttcher SG; Klim S; Haahr H
Clin Pharmacokinet; 2014 Feb; 53(2):175-83. PubMed ID: 24163264
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics of peginterferon lambda-1a following single dose administration to subjects with impaired renal function.
Hruska MW; Adamczyk R; Colston E; Hesney M; Stonier M; Myler H; Bertz R
Br J Clin Pharmacol; 2015 Sep; 80(3):515-24. PubMed ID: 25807956
[TBL] [Abstract][Full Text] [Related]
19. The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol.
Bui K; She F; Sostek M
J Clin Pharmacol; 2014 Dec; 54(12):1375-82. PubMed ID: 24946021
[TBL] [Abstract][Full Text] [Related]
20. Chronic Toxicology Studies of Basal Insulin Peglispro in Rats and Dogs: A Novel, PEGylated Insulin Lispro Analog with a Prolonged Duration of Action.
Byrd RA; Blackbourne JL; Knadler MP; Schultze AE; Vahle JL
Toxicol Pathol; 2017 Apr; 45(3):402-415. PubMed ID: 28421968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
